Infliximab Biosimilars Insights 2020 | DelveInsight

1. Infliximab Biosimilars Insights DelveInsight launched a report titled,“Infliximab Biosimilar Insights, 2020,” which provides comprehensive insights about 35+ companies and 45+ marketed and pipeline drugs in Infliximab Biosimilars landscape. The report covers the marketed and pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Geography Covered Global coverage View full biosimilars-insight Infliximab Overview Infliximab, a chimeric monoclonal antibody, sold under the brand name Remicade among others, is a medication used to treat a number of autoimmune diseases. This includes Crohn's disease, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, psoriasis, psoriatic arthritis, and Behçet's disease. Infliximab is produced by a recombinant cell line cultured by continuous perfusion. Tumor necrosis factor-alpha (TNF-α) is a key proinflammatory cytokine involved in chronic inflammatory diseases. Its hyperactivity and enhanced signalling pathways report: https://www.delveinsight.com/report-store/infliximab-

2. can be observed in inflammatory diseases where it activates further pro-inflammatory cascades. By binding to both the soluble subunit and the membrane-bound precursor of TNF-α 1, infliximab disrupts the interaction of TNF-α with its receptors and may also cause lysis of cells that produce TNF-α 1. Request for sample pages of the report: https://www.delveinsight.com/sample- request/infliximab-biosimilars-insight Infliximab Biosimilars: Drugs Chapters 1. Infliximab Biosimilars: Marketed Drugs Inflectra: Celltrion/Pfizer Renflexis: Merck Crohn’s Disease (moderately to severely active): Can reduce signs and symptoms and induce and maintain remission in adult patients with moderately to severely active Crohn’s disease who haven't responded well to other therapies Pediatric Crohn’s Disease (moderately to severely active): Can reduce signs and symptoms and induce and maintain remission in children (ages 6–17) with moderately to severely active Crohn's disease who haven't responded well to other therapies Ulcerative Colitis (moderately to severely active): Can reduce signs and symptoms, induce and maintain remission, promote intestinal healing, and reduce or stop the need for steroids in adult patients with moderately to severely active ulcerative colitis who haven't responded well to other therapies Pediatric Ulcerative Colitis (moderately to severely active): Can reduce signs and symptoms, induce and maintain remission, promote intestinal healing, and reduce or stop the need for steroids in children (ages 6–17) with moderately to severely active ulcerative colitis who haven't responded well to other therapies 2. Infliximab Biosimilars: Emerging Drugs BCD 055: Biocad CT-P17: Celltrion Read @https://www.delveinsight.com/sample-request/infliximab-biosimilars-insight more about Infliximab Biosimilars

3. Key Pharma players involved: Sandoz Samsung Bioepis Merck Nichiiko Pharmaceutical Aprogen And others. Emerging therapies: Zessly Renflexis/SB2 SB2 Infimab Ixifi And others. Download full report: https://www.delveinsight.com/report-store/infliximab-biosimilars- insight